You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR TRIENTINE TETRAHYDROCHLORIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for trientine tetrahydrochloride

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004339 ↗	Study of Tetrathiomolybdate in Patients With Wilson Disease	Completed	University of Michigan	Phase 3	1994-01-01	OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.
NCT00004339 ↗	Study of Tetrathiomolybdate in Patients With Wilson Disease	Completed	National Center for Research Resources (NCRR)	Phase 3	1994-01-01	OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.
NCT00212355 ↗	Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.	Completed	Nobelpharma	Phase 3	2005-03-01	The purpose of this long-term study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilson's disease among Japanese.
NCT01178112 ↗	Trientine and Carboplatin in Advanced Malignancies	Completed	M.D. Anderson Cancer Center	Phase 1	2010-07-01	The goal of this clinical research study is to find the highest tolerable dose of the combination of trientine and carboplatin that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for trientine tetrahydrochloride

Condition Name

Chart
Table

Condition Name for trientine tetrahydrochloride
Intervention	Trials
Wilson Disease	5
Wilson's Disease	3
Melanoma	1
Advanced Cancers	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for trientine tetrahydrochloride
Intervention	Trials
Hepatolenticular Degeneration	8
Macular Edema	2
Capsule Opacification	1
Cardiomyopathies	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for trientine tetrahydrochloride

Trials by Country

Map
Table

Trials by Country for trientine tetrahydrochloride
Location	Trials
United States	9
United Kingdom	5
Germany	4
Denmark	2
Canada	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for trientine tetrahydrochloride
Location	Trials
Connecticut	3
Texas	2
Michigan	2
California	1
North Carolina	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for trientine tetrahydrochloride

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for trientine tetrahydrochloride
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	3
Phase 2	3
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for trientine tetrahydrochloride
Clinical Trial Phase	Trials
Completed	6
Active, not recruiting	2
Withdrawn	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for trientine tetrahydrochloride

Sponsor Name

Chart
Table

Sponsor Name for trientine tetrahydrochloride
Sponsor	Trials
Univar BV	3
University of British Columbia	2
Orphalan	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for trientine tetrahydrochloride
Sponsor	Trials
Industry	11
Other	11
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.